Vancheri Carlo, Gili Elisa, Failla Marco, Mastruzzo Claudio, Salinaro Elisa Trovato, Lofurno Debora, Pistorio Maria P, La Rosa Cristina, Caruso Massimo, Crimi Nunzio
Department of Internal and Specialistic Medicine, Section of Respiratory Diseases, University of Catania, Italy.
J Allergy Clin Immunol. 2005 Dec;116(6):1242-8. doi: 10.1016/j.jaci.2005.09.025. Epub 2005 Nov 8.
The identification of factors mediating the transition of lung fibroblasts into myofibroblasts is considered fundamental in the comprehension of abnormal reparative processes. Bradykinin, a mediator known for its proinflammatory action, is able to induce cytokine production and contractility in fibroblast cultures.
In this study the ability of bradykinin to drive fibroblast into a myofibroblast phenotype at the cellular and molecular level was evaluated.
alpha-Smooth muscle actin (alpha-SMA) expression and TGF-beta in bradykinin stimulated fibroblasts were tested by means of flow cytometry, Western blot, and RT-PCR. Cell proliferation and collagen production were evaluated by the colorimetric methylthiazol tetrazolium assay and sirius red assay, respectively. Which bradykinin receptor mediates the expression of alpha-SMA was evaluated using selective B1 and B2 blocking agents. Furthermore, the effect of bradykinin on extracellular signal-regulated kinase 1/2 phosphorylation was explored.
Bradykinin caused in lung fibroblasts a significant increase in alpha-SMA at the cellular and molecular level. The B2 receptor was held responsible for this effect because a specific receptor antagonist had entirely blocked this effect. Bradykinin was able to induce fibroblast proliferation and collagen production. Bradykinin significantly activated mitogen-activated protein kinase pathway by phosphorylating extracellular signal-regulated kinase 1/2, whereas PD98059, a specific inhibitor, was able to block myofibroblast induction. Although bradykinin induced an increase of TGF-beta on fibroblasts, the blockage of this cytokine did not alter alpha-SMA expression.
The data support the hypothesis that bradykinin may be involved in bronchial remodeling and lung fibrosis beyond its well recognized proinflammatory activity, also suggesting a new potential therapeutic strategy to control altered reparatory processes.
在理解异常修复过程中,确定介导肺成纤维细胞向肌成纤维细胞转变的因素被认为是至关重要的。缓激肽是一种以促炎作用而闻名的介质,能够在成纤维细胞培养物中诱导细胞因子产生和收缩性。
本研究在细胞和分子水平上评估缓激肽驱动成纤维细胞转变为肌成纤维细胞表型的能力。
通过流式细胞术、蛋白质印迹法和逆转录-聚合酶链反应检测缓激肽刺激的成纤维细胞中α-平滑肌肌动蛋白(α-SMA)的表达和转化生长因子-β(TGF-β)。分别采用比色法噻唑蓝测定法和天狼星红测定法评估细胞增殖和胶原蛋白产生。使用选择性B1和B2阻断剂评估哪种缓激肽受体介导α-SMA的表达。此外,还探讨了缓激肽对细胞外信号调节激酶1/2磷酸化的影响。
缓激肽在细胞和分子水平上使肺成纤维细胞中的α-SMA显著增加。B2受体被认为是造成这种效应的原因,因为一种特异性受体拮抗剂完全阻断了这种效应。缓激肽能够诱导成纤维细胞增殖和胶原蛋白产生。缓激肽通过使细胞外信号调节激酶1/2磷酸化而显著激活丝裂原活化蛋白激酶途径,而特异性抑制剂PD98059能够阻断肌成纤维细胞的诱导。虽然缓激肽诱导成纤维细胞上的TGF-β增加,但该细胞因子的阻断并未改变α-SMA的表达。
数据支持这样的假设,即缓激肽可能在其公认的促炎活性之外还参与支气管重塑和肺纤维化,这也提示了一种控制异常修复过程的新的潜在治疗策略。